US20030109503A1
(en)
*
|
1995-06-06 |
2003-06-12 |
Smithkline Beecham P.L.C. |
Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
|
US6699885B2
(en)
|
1996-01-04 |
2004-03-02 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and methods of using same
|
US5840737A
(en)
|
1996-01-04 |
1998-11-24 |
The Curators Of The University Of Missouri |
Omeprazole solution and method for using same
|
US6489346B1
(en)
|
1996-01-04 |
2002-12-03 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
US6645988B2
(en)
|
1996-01-04 |
2003-11-11 |
Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
US6280745B1
(en)
|
1997-12-23 |
2001-08-28 |
Alliance Pharmaceutical Corp. |
Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
|
WO1998019708A2
(en)
*
|
1996-11-04 |
1998-05-14 |
Union Carbide Chemicals & Plastics Technology Corporation |
Method for enhancing the solubility of substantially water-insoluble compounds
|
US20030124187A1
(en)
*
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
US6010718A
(en)
*
|
1997-04-11 |
2000-01-04 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
US6551616B1
(en)
|
1997-04-11 |
2003-04-22 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
GB9710699D0
(en)
*
|
1997-05-24 |
1997-07-16 |
Danbiosyst Uk |
Gastro-retentive controlled release system
|
WO1998055107A1
(en)
*
|
1997-06-06 |
1998-12-10 |
Depomed, Inc. |
Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
EP1037607B1
(en)
*
|
1997-12-08 |
2004-02-25 |
ALTANA Pharma AG |
Novel suppository form comprising an acid-labile active compound
|
US20060141036A1
(en)
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
US6099859A
(en)
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
WO2000018396A1
(fr)
*
|
1998-09-25 |
2000-04-06 |
Sankyo Company, Limited |
PREPARATIONS A BASE D'INHIBITEUR DE HMG-CoA
|
US20040013613A1
(en)
*
|
2001-05-18 |
2004-01-22 |
Jain Rajeev A |
Rapidly disintegrating solid oral dosage form
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
JP2002525311A
(ja)
*
|
1998-10-01 |
2002-08-13 |
エラン ファーマ インターナショナル,リミティド |
徐放性ナノ粒子組成物
|
US8236352B2
(en)
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
US20020169145A1
(en)
*
|
1998-10-14 |
2002-11-14 |
Rajen Shah |
Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
|
FR2784583B1
(fr)
*
|
1998-10-16 |
2002-01-25 |
Synthelabo |
Composition pharmaceutique a residence gastrique et a liberation controlee
|
DE19850445A1
(de)
*
|
1998-11-02 |
2000-05-04 |
Falk Pharma Gmbh |
Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
|
US7521068B2
(en)
*
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
US6428814B1
(en)
*
|
1999-10-08 |
2002-08-06 |
Elan Pharma International Ltd. |
Bioadhesive nanoparticulate compositions having cationic surface stabilizers
|
US6969529B2
(en)
*
|
2000-09-21 |
2005-11-29 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
US20050137181A1
(en)
*
|
1999-03-17 |
2005-06-23 |
Bonner Ernest L. |
Method for treatment of reactive arthritis or bursitis
|
US6765000B2
(en)
*
|
1999-03-17 |
2004-07-20 |
Bonner Jr Ernest L |
Treatment for reactive arthritis or bursitis
|
US7691831B2
(en)
*
|
1999-03-17 |
2010-04-06 |
Ernest L. Bonner, Jr. |
Pharmaceutical combination and method for treatment of reactive arthritis or bursitis
|
US7884090B2
(en)
*
|
1999-03-17 |
2011-02-08 |
Ernest L. Bonner, Jr. |
Compositions and methods for the treatment of arthritis
|
US6294199B1
(en)
*
|
1999-04-13 |
2001-09-25 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising administering amoxycillin
|
US6878386B1
(en)
|
1999-04-13 |
2005-04-12 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
|
US7250176B1
(en)
*
|
1999-04-13 |
2007-07-31 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection
|
DE19920833A1
(de)
*
|
1999-05-06 |
2000-11-16 |
Lohmann Therapie Syst Lts |
Gastroretentives System mit quellbaren Polymeren
|
AU775995B2
(en)
*
|
1999-06-07 |
2004-08-19 |
Nycomed Gmbh |
Novel preparation and administration form comprising an acid-labile active compound
|
CZ20014379A3
(cs)
*
|
1999-06-11 |
2002-08-14 |
Ranbaxy Laboratories Limited |
Kompozice k maskování chuti a způsob její přípravy
|
IN191239B
(id)
|
1999-06-11 |
2003-10-11 |
Ranbaxy Lab Ltd |
|
PT1251832E
(pt)
|
2000-02-04 |
2007-01-31 |
Depomed Inc |
Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
EP1313486A1
(en)
*
|
2000-02-29 |
2003-05-28 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
|
FR2805761B1
(fr)
*
|
2000-03-02 |
2002-08-30 |
Mainelab |
Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
|
US6242003B1
(en)
|
2000-04-13 |
2001-06-05 |
Novartis Ag |
Organic compounds
|
US6316029B1
(en)
*
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
US20040156872A1
(en)
*
|
2000-05-18 |
2004-08-12 |
Elan Pharma International Ltd. |
Novel nimesulide compositions
|
US6488962B1
(en)
*
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
US6881420B2
(en)
|
2000-06-23 |
2005-04-19 |
Teva Pharmaceutical Industries Ltd. |
Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
|
DE10031043A1
(de)
*
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
|
US7198795B2
(en)
*
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
EP1330236A2
(en)
|
2000-10-12 |
2003-07-30 |
Beecham Pharmaceuticals (Pte) Limited |
Formulation containing amoxicillin
|
US6756057B2
(en)
|
2000-10-12 |
2004-06-29 |
Beecham Pharmaceuticals (Pte) Limited |
Amoxicillin and potassium clavulanate dosage form
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
US20020192299A1
(en)
*
|
2000-12-28 |
2002-12-19 |
Rajneesh Taneja |
Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
|
US20060127474A1
(en)
*
|
2001-04-11 |
2006-06-15 |
Oskar Kalb |
Pharmaceutical compositions comprising fluvastatin
|
US6759058B1
(en)
*
|
2001-04-25 |
2004-07-06 |
Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences |
Enteric-coated proliposomal formulations for poorly water soluble drugs
|
US8658202B2
(en)
|
2001-04-25 |
2014-02-25 |
Western University Of Health Sciences |
Coated drug delivery formulations
|
IN191028B
(id)
*
|
2001-05-17 |
2003-09-13 |
Sun Pharmaceutical Ind Ltd |
|
JP4307995B2
(ja)
*
|
2001-07-12 |
2009-08-05 |
ギブン イメージング リミテッド |
身体の管腔を検査するための装置
|
US7585283B2
(en)
*
|
2001-07-12 |
2009-09-08 |
Given Imaging Ltd. |
Device and method for examining a body lumen
|
US20030050620A1
(en)
*
|
2001-09-07 |
2003-03-13 |
Isa Odidi |
Combinatorial type controlled release drug delivery device
|
US6837696B2
(en)
*
|
2001-09-28 |
2005-01-04 |
Mcneil-Ppc, Inc. |
Apparatus for manufacturing dosage forms
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
US7413751B2
(en)
*
|
2001-10-25 |
2008-08-19 |
Depomed, Inc. |
Methods of treatment using a gastric retained losartan dosage
|
US20070184104A1
(en)
*
|
2001-10-25 |
2007-08-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
US20030104052A1
(en)
*
|
2001-10-25 |
2003-06-05 |
Bret Berner |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US20040006111A1
(en)
*
|
2002-01-25 |
2004-01-08 |
Kenneth Widder |
Transmucosal delivery of proton pump inhibitors
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
JP4598399B2
(ja)
|
2002-02-04 |
2010-12-15 |
エラン ファーマ インターナショナル,リミティド |
表面安定剤としてリゾチームを有するナノ粒子組成物
|
US20040028729A1
(en)
*
|
2002-04-29 |
2004-02-12 |
Shojaei Amir H. |
Pharmaceutical formulations with improved bioavailability
|
US20040082618A1
(en)
*
|
2002-07-03 |
2004-04-29 |
Rajneesh Taneja |
Liquid dosage forms of acid labile drugs
|
EP1551457A1
(en)
*
|
2002-07-16 |
2005-07-13 |
Elan Pharma International Limited |
Liquid dosage compositions of stable nanoparticulate active agents
|
JP2006501310A
(ja)
*
|
2002-08-29 |
2006-01-12 |
アクティブバイオティクス インコーポレイティッド |
クロストリジウム・ディフィシレの感染およびそれに関係する疾患を治療するための方法および試薬
|
US9060941B2
(en)
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US8084058B2
(en)
|
2002-09-20 |
2011-12-27 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7959946B2
(en)
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7785627B2
(en)
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
MY148805A
(en)
*
|
2002-10-16 |
2013-05-31 |
Takeda Pharmaceutical |
Controlled release preparation
|
US20040086566A1
(en)
*
|
2002-11-04 |
2004-05-06 |
Alpharma, Inc. |
Waxy matrix dosage forms
|
JP4494712B2
(ja)
*
|
2002-11-12 |
2010-06-30 |
大日本住友製薬株式会社 |
マルチプルユニット型徐放性製剤
|
US20070243251A1
(en)
*
|
2002-12-20 |
2007-10-18 |
Rajneesh Taneja |
Dosage Forms Containing A PPI, NSAID, and Buffer
|
US6780896B2
(en)
|
2002-12-20 |
2004-08-24 |
Kimberly-Clark Worldwide, Inc. |
Stabilized photoinitiators and applications thereof
|
US7666410B2
(en)
|
2002-12-20 |
2010-02-23 |
Kimberly-Clark Worldwide, Inc. |
Delivery system for functional compounds
|
US20040121004A1
(en)
*
|
2002-12-20 |
2004-06-24 |
Rajneesh Taneja |
Dosage forms containing a PPI, NSAID, and buffer
|
US8409618B2
(en)
|
2002-12-20 |
2013-04-02 |
Kimberly-Clark Worldwide, Inc. |
Odor-reducing quinone compounds
|
EP2286817A3
(en)
|
2003-01-13 |
2011-06-15 |
Edusa Pharmaceuticals, Inc |
Method of treating functional bowel disorders
|
EP1606287B1
(en)
*
|
2003-03-07 |
2013-10-02 |
Merck Sharp & Dohme Corp. |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
CN100439361C
(zh)
|
2003-03-07 |
2008-12-03 |
先灵公司 |
取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
EP1601669B1
(en)
|
2003-03-07 |
2008-12-24 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
US8980322B2
(en)
*
|
2003-03-17 |
2015-03-17 |
Takeda Pharmaceutical Company Limited |
Controlled release composition
|
US8993599B2
(en)
|
2003-07-18 |
2015-03-31 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
US20050013863A1
(en)
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
NZ527142A
(en)
*
|
2003-07-23 |
2006-03-31 |
Douglas Pharmaceuticals Ltd |
A stable suspension formulation
|
WO2005023184A2
(en)
*
|
2003-08-29 |
2005-03-17 |
Advancis Pharmaceuticals Corporation |
Antibiotic product, use and formulation thereof
|
US7879350B2
(en)
|
2003-10-16 |
2011-02-01 |
Kimberly-Clark Worldwide, Inc. |
Method for reducing odor using colloidal nanoparticles
|
US7794737B2
(en)
|
2003-10-16 |
2010-09-14 |
Kimberly-Clark Worldwide, Inc. |
Odor absorbing extrudates
|
US7754197B2
(en)
|
2003-10-16 |
2010-07-13 |
Kimberly-Clark Worldwide, Inc. |
Method for reducing odor using coordinated polydentate compounds
|
US7488520B2
(en)
|
2003-10-16 |
2009-02-10 |
Kimberly-Clark Worldwide, Inc. |
High surface area material blends for odor reduction, articles utilizing such blends and methods of using same
|
US7413550B2
(en)
|
2003-10-16 |
2008-08-19 |
Kimberly-Clark Worldwide, Inc. |
Visual indicating device for bad breath
|
US7837663B2
(en)
|
2003-10-16 |
2010-11-23 |
Kimberly-Clark Worldwide, Inc. |
Odor controlling article including a visual indicating device for monitoring odor absorption
|
US7678367B2
(en)
|
2003-10-16 |
2010-03-16 |
Kimberly-Clark Worldwide, Inc. |
Method for reducing odor using metal-modified particles
|
JP2005132803A
(ja)
*
|
2003-10-31 |
2005-05-26 |
Ono Pharmaceut Co Ltd |
胃内滞留固形剤
|
PT2210605T
(pt)
*
|
2003-11-04 |
2017-04-24 |
Tcd Royalty Sub Llc |
Formas de dosagem única diária de tróspio
|
US8709476B2
(en)
|
2003-11-04 |
2014-04-29 |
Supernus Pharmaceuticals, Inc. |
Compositions of quaternary ammonium compounds containing bioavailability enhancers
|
US20050266032A1
(en)
*
|
2003-12-17 |
2005-12-01 |
Sovereign Pharmaceuticals, Ltd. |
Dosage form containing multiple drugs
|
US20050163843A1
(en)
*
|
2003-12-31 |
2005-07-28 |
Garth Boehm |
Alprazolam formulations
|
EP1559419A1
(en)
*
|
2004-01-23 |
2005-08-03 |
Fournier Laboratories Ireland Limited |
Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
|
WO2005079752A2
(en)
*
|
2004-02-11 |
2005-09-01 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
US8906940B2
(en)
|
2004-05-25 |
2014-12-09 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
US8815916B2
(en)
|
2004-05-25 |
2014-08-26 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
BRPI0512177A
(pt)
*
|
2004-06-17 |
2008-02-12 |
Forest Laboratories |
formulação de liberação modificada de memantina
|
EP1802258A4
(en)
|
2004-09-13 |
2015-09-23 |
Chrono Therapeutics Inc |
BIOSYNCHRONE TRANSDERMAL MEDICINES
|
US8252321B2
(en)
|
2004-09-13 |
2012-08-28 |
Chrono Therapeutics, Inc. |
Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
|
US7282194B2
(en)
*
|
2004-10-05 |
2007-10-16 |
Gp Medical, Inc. |
Nanoparticles for protein drug delivery
|
JP5175553B2
(ja)
*
|
2005-02-01 |
2013-04-03 |
エミスフェアー・テクノロジーズ・インク |
胃内滞留および制御放出型送達系
|
US7803817B2
(en)
*
|
2005-05-11 |
2010-09-28 |
Vecta, Ltd. |
Composition and methods for inhibiting gastric acid secretion
|
US7981908B2
(en)
|
2005-05-11 |
2011-07-19 |
Vecta, Ltd. |
Compositions and methods for inhibiting gastric acid secretion
|
JP2008543845A
(ja)
*
|
2005-06-16 |
2008-12-04 |
フォーレスト ラボラトリーズ, インコーポレイテッド |
放出調節および即放性メマンチンビーズ製剤
|
US20080242642A1
(en)
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US8722650B1
(en)
|
2005-06-24 |
2014-05-13 |
Medicis Pharmaceutical Corporation |
Extended-release minocycline dosage forms
|
US7919483B2
(en)
*
|
2005-06-24 |
2011-04-05 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne
|
US7544373B2
(en)
*
|
2007-04-02 |
2009-06-09 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US8252776B2
(en)
|
2007-04-02 |
2012-08-28 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US20080241235A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US7541347B2
(en)
*
|
2007-04-02 |
2009-06-02 |
Medicis Pharmaceutical Coropration |
Minocycline oral dosage forms for the treatment of acne
|
MX2008000099A
(es)
*
|
2005-06-29 |
2008-03-19 |
Panacea Biotec Ltd |
Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
|
CA2614885C
(en)
|
2005-07-11 |
2015-03-17 |
Pharmena North America Inc. |
Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
|
US8778395B2
(en)
*
|
2005-08-11 |
2014-07-15 |
Andrx Labs, Llc |
Diltiazem controlled release formulation and method of manufacture
|
EP1959923A4
(en)
*
|
2005-08-30 |
2012-05-02 |
Piramal Life Sciences Ltd |
PHARMACEUTICAL METFORMIN COMPOSITION WITH EXTENDED RELEASE AND METHOD OF PREPARATION THEREOF
|
US20070087055A1
(en)
*
|
2005-10-14 |
2007-04-19 |
David Jan |
Directly compressible extended release alprazolam formulation
|
JP2009511606A
(ja)
*
|
2005-10-14 |
2009-03-19 |
ハー・ルンドベック・アクチエゼルスカベット |
エスシタロプラムおよびブプロピオンの低用量の併用を用いる中枢神経系障害の治療方法
|
ZA200804086B
(en)
*
|
2005-10-14 |
2009-07-29 |
Lundbeck & Co As H |
Stable pharmaceutical formulations containing escitalo-pram and bupropion
|
US20070092565A1
(en)
*
|
2005-10-25 |
2007-04-26 |
Pharmascience Inc. |
Gastric retention drug delivery system
|
US20090176882A1
(en)
*
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
CA2654402A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Adel Penhasi |
Multiple unit pharmaceutical formulation
|
CA2653384C
(en)
|
2006-06-30 |
2017-03-14 |
Iceutica Pty Ltd |
Methods for the preparation of biologically active compounds in nanoparticulate form
|
RU2467747C2
(ru)
|
2006-07-25 |
2012-11-27 |
Векта Лтд. |
Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
|
US7731604B2
(en)
*
|
2006-10-31 |
2010-06-08 |
Taylor Made Golf Company, Inc. |
Golf club iron head
|
TR201910825T4
(tr)
|
2006-12-22 |
2019-08-21 |
Ironwood Pharmaceuticals Inc |
Yemek borusu rahatsizliklarini tedavi̇ etmek i̇çi̇n yöntemler ve bi̇leşi̇mler
|
US20090011018A1
(en)
*
|
2006-12-28 |
2009-01-08 |
Astellas Pharma Inc., |
Sustained release formulation for tacrolimus
|
US20080241197A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline dosage forms for the treatment of acne
|
US8071119B2
(en)
|
2007-05-14 |
2011-12-06 |
Sustained Nano Systems Llc |
Controlled release implantable dispensing device and method
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
AU2008282900B2
(en)
*
|
2007-07-27 |
2014-05-22 |
Depomed, Inc. |
Pulsatile gastric retentive dosage forms
|
EP2205245B1
(en)
*
|
2007-10-03 |
2015-06-24 |
WisTa Laboratories Ltd. |
Therapeutic use of diaminophenothiazines
|
JP5607550B2
(ja)
*
|
2008-03-11 |
2014-10-15 |
ディポメド,インコーポレイティド |
非オピオイド鎮痛剤及びオピオイド鎮痛剤の組合せを含む胃保持性持続放出剤形
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
EP2810951B1
(en)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US20090312627A1
(en)
*
|
2008-06-16 |
2009-12-17 |
Matott Laura A |
Radio-labeled ingestible capsule
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
WO2010017310A1
(en)
|
2008-08-06 |
2010-02-11 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne and certain dosage forms thereof
|
JP2012500221A
(ja)
|
2008-08-15 |
2012-01-05 |
ディポメド,インコーポレイティド |
Cns障害の処理及び予防のための胃保持性医薬組成物
|
US8828953B2
(en)
*
|
2009-04-20 |
2014-09-09 |
NaZura BioHealth, Inc. |
Chemosensory receptor ligand-based therapies
|
US9901551B2
(en)
|
2009-04-20 |
2018-02-27 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
EA201101524A1
(ru)
|
2009-04-20 |
2012-07-30 |
Элселикс Терапьютикс, Инк. |
Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
|
JP2012526133A
(ja)
|
2009-05-05 |
2012-10-25 |
ベイポジェニックス インコーポレイテッド |
炎症を低減させるための新規揮発性麻酔薬製剤およびその使用法
|
EP2457561A4
(en)
|
2009-07-06 |
2014-03-05 |
Kyorin Seiyaku Kk |
TABLET HAVING A HOLLOW STRUCTURE
|
US20110104272A1
(en)
*
|
2009-11-05 |
2011-05-05 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
|
EP2509635A4
(en)
*
|
2009-12-08 |
2013-09-18 |
Depomed Inc |
GASTRORETENTIVE PHARMACEUTICAL COMPOSITIONS FOR THE EXTENDED RELEASE OF POLYPEPTIDES
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
WO2011079050A2
(en)
|
2009-12-23 |
2011-06-30 |
The Smart Pill Corporation |
Method of evaluating constipation using an ingestible capsule
|
WO2011080716A2
(en)
|
2010-01-04 |
2011-07-07 |
Wockhardt Limited |
Pharmaceutical composition for modified delivery of actives
|
EP2544666A2
(en)
|
2010-03-09 |
2013-01-16 |
Council of Scientific and Industrial Research |
Gastroretentive, extended release composition of therapeutic agent
|
EP2554168B1
(en)
|
2010-03-29 |
2018-01-24 |
Astellas Pharma Inc. |
Controlled release pharmaceutical composition
|
US8241680B2
(en)
|
2010-06-30 |
2012-08-14 |
Rock Creek Pharmaceuticals, Inc. |
Nutraceutical product containing anatabine and yerba maté
|
EP2603215A4
(en)
|
2010-08-11 |
2015-08-05 |
Philadelphia Health & Educatio |
NEW DOPAMINERGIC D3 RECEPTOR AGONISTS FOR TREATING DYSKINESIA IN PARKINSON'S DISEASE
|
WO2012027331A1
(en)
|
2010-08-27 |
2012-03-01 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US20130053355A1
(en)
|
2011-08-29 |
2013-02-28 |
Rock Creek Pharmaceuticals, Inc. |
Products for anti-inflammation support
|
WO2012054523A2
(en)
|
2010-10-19 |
2012-04-26 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
JP6076913B2
(ja)
|
2010-12-07 |
2017-02-08 |
ドレクセル ユニバーシティ |
癌からの転移を阻害する方法
|
JP6143675B2
(ja)
|
2010-12-16 |
2017-06-07 |
セルジーン コーポレイション |
難溶性薬物の制御放出経口剤形及びその使用
|
US9532977B2
(en)
|
2010-12-16 |
2017-01-03 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
JP2014501787A
(ja)
|
2011-01-07 |
2014-01-23 |
エルセリクス セラピューティクス インコーポレイテッド |
化学感覚受容体リガンドに基づく治療法
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
US8658631B1
(en)
|
2011-05-17 |
2014-02-25 |
Mallinckrodt Llc |
Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
|
US9561241B1
(en)
|
2011-06-28 |
2017-02-07 |
Medicis Pharmaceutical Corporation |
Gastroretentive dosage forms for minocycline
|
US20130017259A1
(en)
|
2011-07-06 |
2013-01-17 |
The Parkinson's Institute |
Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
ES2649410T3
(es)
|
2011-12-21 |
2018-01-11 |
Novira Therapeutics Inc. |
Agentes antivirales para la hepatitis B
|
WO2013158928A2
(en)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
US8313774B1
(en)
|
2012-06-26 |
2012-11-20 |
Magnifica Inc. |
Oral solid composition
|
CA2879454A1
(en)
|
2012-07-19 |
2014-01-23 |
Drexel University |
Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
WO2014026013A2
(en)
|
2012-08-09 |
2014-02-13 |
Dynamis Therapeutics, Inc. |
Methods for maintaining or improving health, well-being and/or a physiological function in a subject
|
CA2896966C
(en)
|
2013-01-07 |
2021-03-30 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cutaneous t cell lymphoma
|
EP2958577A2
(en)
|
2013-02-25 |
2015-12-30 |
Synergy Pharmaceuticals Inc. |
Guanylate cyclase receptor agonists for use in colonic cleansing
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
CN105431144A
(zh)
|
2013-06-05 |
2016-03-23 |
思康脑侒股份有限公司 |
阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
|
CA2917149C
(en)
|
2013-07-02 |
2021-02-02 |
Cineole Corp., Llc |
Antimicrobial formulation comprising isoamyl hexanoates together with propanoic acid and/or isobutyric acid
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
WO2015054649A2
(en)
|
2013-10-10 |
2015-04-16 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
|
US9908915B2
(en)
|
2013-11-26 |
2018-03-06 |
Yale University |
Cell-penetrating compositions and methods using same
|
US10258615B2
(en)
|
2013-12-09 |
2019-04-16 |
Thomas Jefferson University |
Methods of treating a neurodegenerative disease in a mammal in need thereof
|
EP3079663A1
(en)
|
2013-12-13 |
2016-10-19 |
Biogen MA Inc. |
Controlled release dosage form for once daily administration of dimethyl fumarate
|
EP3128996B1
(en)
|
2014-04-07 |
2021-06-02 |
University of Rochester |
Novel 7-dehydrocholesterol derivatives and methods using same
|
CN106714809A
(zh)
|
2014-08-20 |
2017-05-24 |
耶鲁大学 |
对治疗或预防肝脏疾病或障碍和促进体重减轻有用的新型组合物和方法
|
JP2018511355A
(ja)
|
2015-01-28 |
2018-04-26 |
クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. |
薬剤送達方法及びシステム
|
EP3267875A4
(en)
|
2015-03-12 |
2018-12-05 |
Chrono Therapeutics Inc. |
Craving input and support system
|
WO2016174664A1
(en)
|
2015-04-29 |
2016-11-03 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
US10597368B2
(en)
|
2015-05-08 |
2020-03-24 |
Brown University |
Syringolin analogues and methods of making and using same
|
KR20180005249A
(ko)
|
2015-05-19 |
2018-01-15 |
예일 유니버시티 |
병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법
|
US10829440B2
(en)
|
2015-06-12 |
2020-11-10 |
Brown University |
Antibacterial compounds and methods of making and using same
|
EA201890068A1
(ru)
|
2015-06-17 |
2018-09-28 |
Байоджен Ма Инк. |
Частицы диметилфумарата и фармацевтические композиции на их основе
|
JP6731427B2
(ja)
|
2015-06-30 |
2020-07-29 |
ネウラッド リミテッドNeurad Ltd. |
新規の呼吸制御調節化合物、およびこれを製造し、かつ使用する方法
|
WO2017075145A1
(en)
|
2015-10-28 |
2017-05-04 |
Yale University |
Quinoline amides and methods of using same
|
WO2017083348A1
(en)
|
2015-11-11 |
2017-05-18 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
JP2018537093A
(ja)
|
2015-11-20 |
2018-12-20 |
イエール ユニバーシティ |
異所性石灰化障害を治療するための組成物およびそれを使用する方法
|
JP2019506383A
(ja)
|
2016-01-11 |
2019-03-07 |
シナジー ファーマシューティカルズ インコーポレイテッド |
潰瘍性大腸炎を治療するための製剤および方法
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
US10292977B2
(en)
|
2016-04-11 |
2019-05-21 |
Neurocea, LLC |
Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
|
US10143687B2
(en)
|
2016-04-11 |
2018-12-04 |
Neurocea, LLC |
Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
|
US20190119364A1
(en)
|
2016-04-29 |
2019-04-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds and compositions useful for treating metabolic syndrome, and methods using same
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
US20210330599A1
(en)
|
2016-08-01 |
2021-10-28 |
University Of Rochester |
Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
|
US11390859B2
(en)
|
2016-08-05 |
2022-07-19 |
Yale University |
Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
|
AU2017321791B2
(en)
|
2016-09-01 |
2022-03-24 |
Mebias Discovery, Inc. |
Substituted ureas and methods of making and using same
|
KR102522060B1
(ko)
|
2016-11-07 |
2023-04-14 |
아뷰터스 바이오파마 코포레이션 |
치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법
|
WO2018112078A1
(en)
|
2016-12-14 |
2018-06-21 |
Amgen Inc. |
Gastro-retentive modified release dosage forms for oprozomib and process to make thereof
|
JP2020503950A
(ja)
|
2017-01-06 |
2020-02-06 |
クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. |
経皮薬剤送達の装置及び方法
|
EP4219486A1
(en)
|
2017-01-19 |
2023-08-02 |
Temple University of the Commonwealth System of Higher Education |
Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
|
MA49014A
(fr)
|
2017-03-21 |
2020-02-05 |
Arbutus Biopharma Corp |
Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
|
US11166953B2
(en)
|
2017-04-17 |
2021-11-09 |
Yale University |
Compounds, compositions and methods of treating or preventing acute lung injury
|
WO2019023621A1
(en)
|
2017-07-28 |
2019-01-31 |
Yale University |
ANTICANCER DRUGS AND METHODS OF MAKING AND USING THEM
|
AU2018330171A1
(en)
|
2017-09-08 |
2020-03-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers
|
US20200323895A1
(en)
|
2017-11-27 |
2020-10-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Compounds, Compositions, and Methods for Treating And/Or Preventing Periodontal Disease
|
US11337920B2
(en)
|
2017-12-18 |
2022-05-24 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
|
WO2019126218A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
|
US11666546B2
(en)
|
2017-12-18 |
2023-06-06 |
Tris Pharma, Inc |
GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
WO2019125184A1
(en)
|
2017-12-19 |
2019-06-27 |
Auckland Uniservices Limited |
Use of biomarker in cancer therapy
|
AU2019212241A1
(en)
|
2018-01-24 |
2020-08-13 |
The Rockefeller University |
Antibacterial compounds, compositions thereof, and methods using same
|
JP7125791B2
(ja)
|
2018-05-23 |
2022-08-25 |
シャンハイ ダブリュディー ファーマシューティカル カンパニー,リミティド |
活性薬物成分の放出制御システムおよびその製造方法
|
US11911513B2
(en)
|
2018-05-23 |
2024-02-27 |
Shanghai Wd Pharmaceutical Co., Ltd |
Controlled-release system of active pharmaceutical ingredient and preparation method therefor
|
CN114191307A
(zh)
|
2020-09-17 |
2022-03-18 |
上海汉都医药科技有限公司 |
一种口腔滞留装置及其制备方法
|
MX2020012805A
(es)
|
2018-05-29 |
2021-02-15 |
Cersci Therapeutics Inc |
Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.
|
CA3101966A1
(en)
|
2018-05-29 |
2019-12-05 |
Morningside Venture Investments Limited |
Drug delivery methods and systems
|
CA3113377A1
(en)
|
2018-10-11 |
2020-04-16 |
Sanifit Therapeutics S.A. |
Inositol phosphates for the treatment of ectopic calcification
|
TWI827760B
(zh)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
US20210395218A1
(en)
|
2018-12-17 |
2021-12-23 |
Philip Morris Products S.A. |
3-(1,2,3,6-tetrahydropyridin-2-yl) pyridine glutarate or a pharmaceutically acceptable solvate thereof
|
KR20210148078A
(ko)
|
2019-01-30 |
2021-12-07 |
사니핏 테라퓨틱스 에스.에이. |
조직 관류 증가에 사용하기 위한 이노시톨 포스페이트 화합물
|
US20200246316A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
US20200246317A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
CA3139109A1
(en)
|
2019-05-09 |
2020-11-12 |
The Feinstein Institutes For Medical Research |
Hmgb1 antagonist
|
US11555010B2
(en)
|
2019-07-25 |
2023-01-17 |
Brown University |
Diamide antimicrobial agents
|
EP3818983A1
(en)
|
2019-11-11 |
2021-05-12 |
Sanifit Therapeutics S.A. |
Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
EP4162036A1
(en)
|
2020-06-09 |
2023-04-12 |
Inozyme Pharma, Inc. |
Soluble enpp1 or enpp3 proteins and uses thereof
|
US11529310B2
(en)
|
2020-12-08 |
2022-12-20 |
Ruminant Biotech Corp Limited |
Devices and methods for delivery of substances to animals
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
EP4036097A1
(en)
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Ip4-4,6 substituted derivative compounds
|
WO2024023360A1
(en)
|
2022-07-29 |
2024-02-01 |
Sanifit Therapeutics, S.A. |
Ip5 substituted compounds
|
WO2024023359A1
(en)
|
2022-07-29 |
2024-02-01 |
Sanifit Therapeutics, S.A. |
Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
WO2024052895A1
(en)
|
2022-09-06 |
2024-03-14 |
Hadasit Medical Research Services And Development Ltd |
Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
|